Kairos Pharma earnings were -$5.8M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest KAPA earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$1.7M, up 21.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, KAPA reported annual earnings of -$5.4M, with 109.3% growth.
Kairos Pharma (NYSEMKT: KAPA) reported Q1 2026 earnings per share (EPS) of -$0.08, up 0% year over year. Total KAPA earnings for the quarter were -$1.65 million. In the same quarter last year, Kairos Pharma's earnings per share (EPS) was -$0.08.
As of the last Kairos Pharma earnings report, Kairos Pharma is currently losing money. Kairos Pharma's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$5.84 million, a 64.85% increase year over year.
What was KAPA's earnings growth in the past year?
As of Kairos Pharma's earnings date in Q2 2026, Kairos Pharma's earnings has grown year over year. KAPA earnings in the past year totalled -$5.84 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.